Delivery of antimigraine drugs to the brain through novel drug delivery systems
Novel Drug Delivery Systems in the management of CNS Disorders, Page: 371-392
2025
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Migraine is the second most common cause of the neurological disorder that is characterized by a severe headache. The main goal of migraine treatment is to provide quick relief to the patient. However, the blood-brain barrier is the main constraint for drug penetration from the conventional dosage form. Additionally, erratic absorption and migraine-induced nausea and vomiting from the oral route limit the patient's compliance due to first-pass metabolism and delay in the onset of action. Many anti-migraine drugs currently used in treatment have low bioavailability and solubility. This imposes the need for novel drug delivery for existing drugs which can enhance drug delivery to the brain. Therefore, this review focused on all recent drug delivery systems developed for migraine treatment.
Bibliographic Details
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know